Product Code: ETC8838876 | Publication Date: Sep 2024 | Updated Date: Jun 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Therapeutic options for Crohns Disease in the Philippines primarily include corticosteroids, immunomodulators, and biologic drugs. Multinational pharmaceutical firms dominate this space, offering innovative treatments, albeit at high costs. As diagnosis rates improve, demand for targeted biologics and patient support programs is likely to grow.
As part of the broader IBD field, Crohns therapeuticsincluding biologics, small molecules, and immunomodulatorsare gaining traction. Focus is placed on accessibility and chronic care patient management, prompting private hospitals to adopt advanced treatment protocols.
Therapeutics for Crohns Disease are expensive and often imported, making them inaccessible to a large section of the population. Reimbursement systems are underdeveloped, and generic alternatives are scarce. Additionally, local clinical trials are limited, impeding evidence-based adjustments to treatment protocols tailored to Filipino patients.
The therapeutics market for Crohns disease in the Philippines presents an opportunity for pharmaceutical investors to introduce biologic drugs, biosimilars, and advanced immunomodulators. Collaborating with hospitals and gastroenterologists for clinical trials, and leveraging telemedicine for rural outreach, can further accelerate therapeutic adoption and revenue generation.
The government regulates biologics and specialty drugs used in Crohns treatment through the FDA. Policies focus on pharmacovigilance and price regulation under the Maximum Drug Retail Price (MDRP) program. Public procurement through DOH hospitals also supports treatment access for eligible patients.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Crohns Disease Therapeutics Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Crohns Disease Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Crohns Disease Therapeutics Market - Industry Life Cycle |
3.4 Philippines Crohns Disease Therapeutics Market - Porter's Five Forces |
3.5 Philippines Crohns Disease Therapeutics Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
4 Philippines Crohns Disease Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Crohns Disease Therapeutics Market Trends |
6 Philippines Crohns Disease Therapeutics Market, By Types |
6.1 Philippines Crohns Disease Therapeutics Market, By Therapy Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Crohns Disease Therapeutics Market Revenues & Volume, By Therapy Type, 2021- 2031F |
6.1.3 Philippines Crohns Disease Therapeutics Market Revenues & Volume, By Non-Surgical, 2021- 2031F |
6.1.4 Philippines Crohns Disease Therapeutics Market Revenues & Volume, By Surgical, 2021- 2031F |
7 Philippines Crohns Disease Therapeutics Market Import-Export Trade Statistics |
7.1 Philippines Crohns Disease Therapeutics Market Export to Major Countries |
7.2 Philippines Crohns Disease Therapeutics Market Imports from Major Countries |
8 Philippines Crohns Disease Therapeutics Market Key Performance Indicators |
9 Philippines Crohns Disease Therapeutics Market - Opportunity Assessment |
9.1 Philippines Crohns Disease Therapeutics Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
10 Philippines Crohns Disease Therapeutics Market - Competitive Landscape |
10.1 Philippines Crohns Disease Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Philippines Crohns Disease Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |